BRPI0925000B8 - solução de n,n-diamino-difenil sulfona e seu uso terapêutico - Google Patents
solução de n,n-diamino-difenil sulfona e seu uso terapêuticoInfo
- Publication number
- BRPI0925000B8 BRPI0925000B8 BRPI0925000A BRPI0925000A BRPI0925000B8 BR PI0925000 B8 BRPI0925000 B8 BR PI0925000B8 BR PI0925000 A BRPI0925000 A BR PI0925000A BR PI0925000 A BRPI0925000 A BR PI0925000A BR PI0925000 B8 BRPI0925000 B8 BR PI0925000B8
- Authority
- BR
- Brazil
- Prior art keywords
- diaminodiphenylsulfine
- soluble
- cerebral infarction
- prepared
- diamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
formas farmacêuticas solúveis da n,n' - diaminodifenilsulfona para uso ótimo no tratamento de diversas enfermidades a presente invenção, tem por objetivo demonstrar que se pode preparar uma forma farmacêutica solúvel da n,n'-diaminodifenilsulfina, útil na obtenção de um medicamento ótimo para seu emprego contra o enfarte cerebral, a epilepsia , a lesão traumática da medula espinhal, a lesão crânio-encefálica , a lepra , as infecções por pneumocystis carinii e qualquer condição em que se requeria uma absorção rápida e completa do composto. como exemplo representativo desta aplicação , a dissolução da n,n'diaminodifenilsulfona foi avaliada como neuroprotetor, num modelo de enfarte agudo cerebral em ratas. neste estudo a n,n'-diaminodufenilsulfato demonstrou uma prevenção significativa do dano cerebral , sem apresentar-se efeitos adversos nos animais. mostra-se também que as formas farmacêuticas solúveis preparadas desta forma , produzem concentrações asnguíneas máximas 30 minutos da administração pela via oral e imediatamente pela via intravenosa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2009004635A MX2009004635A (es) | 2009-04-29 | 2009-04-29 | Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades. |
| MXMX/A/2009/004635 | 2009-04-29 | ||
| PCT/MX2009/000105 WO2010126349A1 (es) | 2009-04-29 | 2009-10-05 | Formas farmacéuticas solubles de la n, n'-diaminodifenilsulfona para uso óptimo en el tratamiento de diversas enfermedades |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0925000B1 BRPI0925000B1 (pt) | 2020-08-18 |
| BRPI0925000B8 true BRPI0925000B8 (pt) | 2021-05-25 |
Family
ID=43032353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0925000A BRPI0925000B8 (pt) | 2009-04-29 | 2009-10-05 | solução de n,n-diamino-difenil sulfona e seu uso terapêutico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8680156B2 (pt) |
| EP (1) | EP2425829B1 (pt) |
| JP (1) | JP5671010B2 (pt) |
| KR (1) | KR101631945B1 (pt) |
| CN (1) | CN102548547B (pt) |
| BR (1) | BRPI0925000B8 (pt) |
| CA (1) | CA2760017C (pt) |
| CO (1) | CO6470840A2 (pt) |
| HK (1) | HK1172568A1 (pt) |
| MX (1) | MX2009004635A (pt) |
| RU (1) | RU2538658C2 (pt) |
| WO (1) | WO2010126349A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101875705B1 (ko) * | 2011-12-07 | 2018-07-06 | 삼성전자주식회사 | 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물 |
| KR20160047318A (ko) * | 2014-10-22 | 2016-05-02 | 삼성전자주식회사 | 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721242A (en) * | 1993-06-17 | 1998-02-24 | Hoffmann-La Roche Inc. | Antibiotic combination |
| RU2200550C2 (ru) * | 1999-10-29 | 2003-03-20 | Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством | Новые лекарственные формы димоцифона в терапии лепры, зудящих и аллергодерматозов, герпетиформного дерматита дюринга |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| MXPA03006549A (es) * | 2003-07-22 | 2004-03-18 | Univ Autonoma Metropolitana | Uso de la dapsona como neuroprotector en el infarto cerebral. |
| US20060204526A1 (en) | 2003-08-13 | 2006-09-14 | Lathrop Robert W | Emulsive composition containing Dapsone |
| WO2009108147A1 (en) | 2008-02-27 | 2009-09-03 | Qlt Usa, Inc. | Dapsone to treat rosascea |
-
2009
- 2009-04-29 MX MX2009004635A patent/MX2009004635A/es active IP Right Grant
- 2009-10-05 US US13/266,892 patent/US8680156B2/en active Active - Reinstated
- 2009-10-05 WO PCT/MX2009/000105 patent/WO2010126349A1/es active Application Filing
- 2009-10-05 CA CA2760017A patent/CA2760017C/en active Active
- 2009-10-05 JP JP2012508413A patent/JP5671010B2/ja active Active
- 2009-10-05 RU RU2011145768/15A patent/RU2538658C2/ru active
- 2009-10-05 KR KR1020117028275A patent/KR101631945B1/ko active IP Right Grant
- 2009-10-05 BR BRPI0925000A patent/BRPI0925000B8/pt active IP Right Grant
- 2009-10-05 CN CN200980158985.8A patent/CN102548547B/zh active Active
- 2009-10-05 EP EP09844101.7A patent/EP2425829B1/en active Active
-
2011
- 2011-11-29 CO CO11164315A patent/CO6470840A2/es active IP Right Grant
-
2012
- 2012-12-28 HK HK12113527.1A patent/HK1172568A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2760017A1 (en) | 2010-11-04 |
| RU2538658C2 (ru) | 2015-01-10 |
| EP2425829B1 (en) | 2015-07-22 |
| CN102548547B (zh) | 2014-10-15 |
| HK1172568A1 (en) | 2013-04-26 |
| CO6470840A2 (es) | 2012-06-29 |
| RU2011145768A (ru) | 2013-06-10 |
| CA2760017C (en) | 2016-02-23 |
| JP2012525379A (ja) | 2012-10-22 |
| MX2009004635A (es) | 2010-10-29 |
| JP5671010B2 (ja) | 2015-02-18 |
| US8680156B2 (en) | 2014-03-25 |
| EP2425829A1 (en) | 2012-03-07 |
| BRPI0925000B1 (pt) | 2020-08-18 |
| US20120157541A1 (en) | 2012-06-21 |
| CN102548547A (zh) | 2012-07-04 |
| KR20150124460A (ko) | 2015-11-06 |
| EP2425829A4 (en) | 2012-10-17 |
| WO2010126349A1 (es) | 2010-11-04 |
| KR101631945B1 (ko) | 2016-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| AR054249A1 (es) | Tratamiento de enfermedades del tejido conectivo de la piel | |
| BRPI0513243A (pt) | composições oftálmicas e métodos para tratar condições oftálmicas | |
| BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
| PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| RU2016106829A (ru) | Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей | |
| HRP20180327T1 (hr) | Sredstva za uporabu u slučaju intolerancije na fruktozu | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| DE602006017728D1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
| AR072668A1 (es) | Encapsulacion de agentes biologicamente activos | |
| BR112013027010A2 (pt) | método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos | |
| BRPI0925000B8 (pt) | solução de n,n-diamino-difenil sulfona e seu uso terapêutico | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| BR112015022084A2 (pt) | composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol | |
| AR112070A1 (es) | Solución de infusión de levodopa | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
| BRPI0602179A (pt) | composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação | |
| WO2006089120A3 (en) | Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury | |
| SV2013004582A (es) | Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias | |
| WO2007144889A3 (en) | Treatment of neurofibromatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |